New Therapies for Hypophosphatemia-Related to FGF23 Excess
Sign Up to like & getrecommendations! Published in 2020 at "Calcified Tissue International"
DOI: 10.1007/s00223-020-00705-3
Abstract: FGF23 is a hormone produced by osteocytes in response to an elevation in the concentration of extracellular phosphate. Excess production of FGF23 by bone cells, or rarely by tumors, is the hormonal basis for several… read more here.
Keywords: fgf23; fgf23 mediated; treatment; new therapies ... See more keywords
AB0925 MULTIPLE FRACTURES DUE TO IRON-INDUCED AND FGF23-MEDIATED HYPOPHOSPHATAEMIC OSTEOMALACIA: AN UNKNOWN ADVERSE EFFECT
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.5938
Abstract: The use of a specific and widely used type of intravenous ferrotherapy, ferric carboxymaltose (FCM), has been linked to the development of an asymptomatic and transient hypophosphataemia. However, in recent years it has been published… read more here.
Keywords: phosphate; none declared; fgf23 mediated; adverse effect ... See more keywords